Objective: Mirabegron is widely considered as an effective and safe drug for patients with overactive bladder (OAB). However, there is no evidence regarding the efficacy of mirabegron in human T cell lymphotropic virus-1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients with OAB symptoms. The aim of the present study was to clarify the efficacy of mirabegron in HAM/TSP patients with OAB symptoms.
general, HAM/TSP is characterized by slow progression of lower limb sensory disturbances and movement disorder accompanied by neurogenic bladder dysfunction caused by chronic inflammation in the central nervous system (CNS), especially the lower thoracic spinal cord. 5 Both storage and voiding symptoms are very common and are seen even in the very early phase of HAM/TSP. In addition, these symptoms sometimes precede the development of paraparesis by many years. 5 Moreover, lower urinary tract symptoms (LUTS) affect the quality of life (QoL) not only in HAM/TSP patients, but also in HTLV-1-infected individuals. 6 Urinary symptoms occur in up to 100% of patients with HAM/TSP, and overactive bladder (OAB) is the main manifestation of HAM/TSP. 7 OAB associated with HAM/TSP is multifarious and affects patients' QoL. However, there are only a few reports on the efficacy of medications for OAB associated with HAM/TSP. Moreover, HAM/TSP patients with LUTS are not fully satisfied with the efficacy of some medications. [7] [8] [9] [10] In some of these patients, the anticholinergic agents prescribed for OAB symptoms caused severe adverse effects, such as constipation and dry mouth, which are autonomic symptoms. In contrast, although methylprednisolone has often been used in HAM/TSP patients with neurogenic bladder, it has limitations in improving LUTS. 10 In addition to these treatments, some advanced medical treatments, such as botulinum toxin type A, have been tried. [7] [8] [9] However, these studies did not conclusively prove the efficacy and safety of these treatments because of the small number of patients involved. Therefore, the lack of established curative treatments for LUTS in HAM/TSP patients with OAB symptoms is a critical problem.
Mirabegron is a β 3 -adrenoreceptor agonist and is approved for the treatment of OAB worldwide. One of the important characteristics of mirabegron is that it causes fewer adverse events, such as constipation or dry mouth, than anticholinergic agents. [11] [12] [13] There-
fore, mirabegron appears to be advantageous in maintaining QoL in HAM/TSP patients undergoing treatment for OAB. However, there are few data regarding the adverse events associated with mirabegron treatment in these patients. In addition, the efficacy of mirabegron for OAB symptoms associated with HAM/TSP based on subjective parameters and urodynamic assessment has not been fully investigated. Hence, the aim of the present study was to clarify the efficacy and safety of mirabegron in HAM/TSP patients with OAB.
| METHODS
The study protocol was approved by the Clinical Studies Review
Board of Nagasaki University Hospital and the study was performed in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all patients enrolled in the study.
| Patients and study design
HAM/TSP patients with OAB symptoms were recruited at the Naga- 
| UFM assessment
The maximum flow rate (Q max ) was measured using the Duet Logic G2 system (Mediwatch UK, Rugby, UK) on free UFM and PVR using transabdominal ultrasound (HI VISION Avius; Hitachi-Aloka Medical, Tokyo, Japan).
| Statistical analyses
All data are presented as mean AE SD. Wilcoxon's signed-rank test was used to evaluate changes in subjective symptoms based on the OABSS and IPSS, and in objective symptoms assessed using UFM and PVR. All tests were 2-sided and P < .05 was considered significant. All statistical analyses were performed using JMP 13 (SAS Institute, Cary, NC, USA).
| RESULTS
Nineteen women were enrolled in the present study. As indicated in total OABSS (from 7.9 AE 2.2 to 4.3 AE 2.8; P < .001), night-time frequency (Question (Q) 2 on the OABSS; P < .001), urgency (OABSS Q3; P < 0.001), and urgency incontinence (OABSS Q4; P = .004). In addition, mirabegron therapy improved the total IPSS (from 12.2 AE 3.9 to 9.2 AE 2.6, P < .001), as well as the urgency (IPSS Q4; P < .001), nocturia (IPSS Q7; P < .001), storage symptoms (IPSS Q2 + Q4 + Q7; P < .001) subscale scores and the IPSS-QOL (from 4.3 AE 1.1 to 3.6 AE 1.0; P < .001). However, there were no significant changes in the scores for incomplete emptying (IPSS Q1; P = .520), intermittency (IPSS Q3; P < 1.000), weak stream (IPSS Q5; P < .555), straining (IPSS Q6; P < 1.000), or voiding symptoms (IPSS Q1 + Q3 + Q5 + Q6; P < .889) following mirabegron therapy.
Changes in objective measures (i.e. bladder capacity, VV, Q max , and PVR) are given in Table 3 . There were no significant changes from baseline to 12 weeks after mirabegron therapy in either bladder capacity (from 287.9 AE 153.6 mL to 283.0 AE 120.8 mL; P = .891), VV (from 130.0 AE 111.8 mL to 90.4 AE 85.0 mL; P = .120), Q max , or PVR (P = .598 and P = .121, respectively).
Differences in characteristics between the failure and improved groups (based on changes in OABSS Q3) are given in Table 4 .
Patients in the improved group were younger than those in the failure group. In addition, OMDS in the failure group was higher than in the improved group. However, there were no other significant differences between the 2 groups. The changes in OABSS and IPSS in each group are given in Table 5 . There were improvements in total OABSS and IPSS Q7 (nocturia) in both the improved and failure groups. In the case of objective symptoms, UFM assessment showed that PVR in the failure group increased significantly after mirabegron administration (Table 6) .
A safety analysis was performed on all patients during the study.
One patient (5.3%) complained of dry mouth. However, because this adverse effect was very mild, the patient did not discontinue mirabegron. None of the patients complained of constipation, dry eye, or a decline in cognitive function. In addition, none of the patients with hypertension experienced worsening of their blood pressure levels and pulse rate. Hence, all patients completed this clinical study, including all the scheduled examinations during the study period.
| DISCUSSION
The results of the present study indicate that the oral administration of mirabegron improves subjective symptoms, as assessed by OABSS, total IPSS, and IPSS QoL, in HAM/TSP patients with neurogenic
OAB. The present study is the first to report on changes in subjective symptoms following mirabegron treatment in HAM/TSP patients with neurogenic OAB. In addition, oral mirabegron therapy was found to be safe for HAM/TSP patients, and the mirabegron therapy did not exacerbate the objective parameters Q max and PVR.
In patients with HAM/TSP, OAB symptoms such as nocturia and urgency are more frequent than voiding symptoms. 16 In addition, it is considered that OAB symptoms are LUTS, and even patients who are Botulinum toxin type A is usually injected intravesically and is an invasive therapy. In addition, it has been reported that HAM/TSP patients with neurogenic bladder may also have urinary tract infection and voiding dysfunction. 21 In fact, 1 of the 3 patients in report of Carneiro et al. 8 showed an increase in PVR from 32 to 410 mL after botulinum toxin type A intravesical injection therapy. 8 Thus, an effective treatment strategy for lower urinary tract dysfunction in HAM/TSP patients has not yet been established.
Mirabegron, which is approved for the treatment of OAB, is a specific agonist acting on β 3 -adrenoceptors in the human bladder, the stimulation of which leads to active relaxation of the detrusor muscle in the storage phase, which, in turn, increases bladder capacity without exerting an effect on voiding. 22 The efficacy and safety of mirabegron have been reported in several randomized trials, for example the SCORPIO and TAURUS studies. Unless indicated otherwise, data are given as the mean AE SD (range) or as n (%).
a Patients were divided into 2 groups, an improved group (in which the score for Question 3 on the overactive bladder symptom score (urgency) decreased by ≥1 point) and a failure group. CISC, clean intermittent self-catheterization; N/A, not applicable; OMDS, Osame's motor disability score. Patients were divided into 2 groups (failure and improved groups)
on the basis of changes in the OABSS Q3 score. The success rate for mirabegron treatment was 73.7% (14/19) . In the improved group, there were significant improvements in the scores for Q2 (nocturia), Q3 (urgency), Q4 (urgency incontinence), and the total score on the OABSS, as well as in scores for Q2 (frequency), Q4 (urgency), Q7
(nocturia), stage symptoms (Q2 + Q4 + Q7), and QoL on the IPSS.
The total OABSS, as well as scores for Q7 (nocturia) and storage symptoms on the IPSS improved significantly, even in the failure group. However, we could not determine the effectiveness of mirabegron for objective symptoms, namely bladder capacity, PVR, VV, and Q max . Although there were no statistically significant changes in VV and PVR in any patient, VV decreased and PVR increased after the study period. In the failure group, all patients performed CISC, and PVR increased significantly after mirabegron treatment. This could be because the present study included 14 patients who had already performed CISC and were expected to have irreversible voiding dysfunction. Moreover, we did not use a frequency volume chart to evaluate the bladder capacity of patients.
In the present study, we paid special attention to adverse events, especially dry mouth and constipation. In previous studies, the rate of adverse events associated with 50 mg mirabegron was similar to that associated with placebo, and was significantly lower than that associated with the antimuscarinic drug tolterodine (4 mg). 12, 23 In addition, several studies have reported that the incidence of adverse events, such as dry mouth and constipation, was similar between patients treated with mirabegron and those treated with placebo. 11, 12, 24 However, some studies reported that many HAM/TSP patients suffered from constipation and dry mouth even before treatment. [25] [26] [27] Thus, mirabegron may be more convenient to administer in HAM/TSP patients with OAB than anticholinergic agents. In fact, in the present study, only 1 patient developed mild dry mouth and no patient had constipation. Hence, mirabegron is considered to be a potential treatment option even for HAM/TSP patients who have comorbidities, including autonomic symptoms.
The major limitations of the present study include the relatively small number of patients included and the short observation period.
The present study was an open label study and not placebo controlled. In addition, the study population did not include male patients. The patients included in the study did not undergo urody- In conclusion, the results of the present study indicate that the oral administration of mirabegron is effective against subjective symptoms in HAM/TSP patients with OAB. In addition, mirabegron was considered a safe and tolerable therapeutic agent in these patients. Data are the mean AE SD.
a Patients were divided into 2 groups, an improved group (in which the score for Question 3 on the overactive bladder symptom score (urgency) decreased by ≥1 point) and a failure group.
